Paxlovid (nirmatrelvir/ritonavir)
Paxlovid is a combination drug containing two antiviral agents, nirmatrelvir and ritonavir. It is used for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years and older who weigh at least 40 kilograms.
Nirmatrelvir and ritonavir
Paxlovid should be taken orally, with or without food, twice daily for 5 days.
Routes of Administration
Oral
The recommended dosage of Paxlovid is two tablets (300 mg of nirmatrelvir and 100 mg of ritonavir) taken orally, with or without food, twice daily for 5 days.
Strength
Each tablet of Paxlovid contains 300 mg of nirmatrelvir and 100 mg of ritonavir.
Paxlovid is indicated for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years and older who weigh at least 40 kilograms.
Paxlovid is available as tablets
Paxlovid is indicated for the treatment of mild to moderate COVID-19 in adults and pediatric patients aged 12 years and older who weigh at least 40 kilograms.
Paxlovid is contraindicated in patients with known hypersensitivity to nirmatrelvir or ritonavir.
composition
Each tablet of Paxlovid contains 300 mg of nirmatrelvir and 100 mg of ritonavir.
Packaging
Each package contains 60 tablets (6 blister cards of 10 tablets each).
Storage conditions
Paxlovid should be stored at room temperature between 20°C to 25°C (68°F to 77°F).
Sale terms
Paxlovid is a prescription drug and is available only with a prescription from a healthcare provider.
Telephone
Pfizer Inc. can be reached at 1-800-438-1985.
Common side effects of Paxlovid include diarrhea, nausea, vomiting, and headache. Serious allergic reactions may occur in rare cases.
Paxlovid should be used with caution in patients with liver or kidney disease.
No specific information is available about the effects of an overdose of Paxlovid.
Paxlovid may interact with other medications, including strong CYP3A inhibitors and inducers.
ATC Code
Expiry date
Price Range
Antiviral agents for systemic use
Antivirals for systemic use, protease inhibitors
Nirmatrelvir and ritonavir work together to inhibit the replication of the SARS-CoV-2 virus in the body.
The pharmacokinetics of nirmatrelvir and ritonavir have not been extensively studied, but they are both metabolized by the liver and eliminated from the body through the feces and urine.
The efficacy of Paxlovid was evaluated in a randomized, double-blind, placebo-controlled clinical trial involving 1,216 participants with mild to moderate COVID-19. The results showed that treatment with Paxlovid reduced the risk of hospitalization or death by 89% compared to placebo.
The efficacy and safety of Paxlovid were evaluated in a randomized, double-blind, placebo-controlled clinical trial involving 1,216 participants with mild to moderate COVID-19. The trial included participants who were at least 12 years of age and weighed at least 40 kilograms, and had tested positive for SARS-CoV-2 within 3 days of enrollment. The participants were randomly assigned to receive either Paxlovid or placebo.
The results of the clinical trial showed that treatment with Paxlovid reduced the risk of hospitalization or death by 89% compared to placebo. Among the participants who received Paxlovid, 0.8% were hospitalized or died, compared to 7.0% of participants who received placebo. In addition, the time to symptom resolution was shorter in the Paxlovid group compared to the placebo group. The safety profile of Paxlovid was similar to placebo, with no new safety concerns identified.
